Table 3. Comparison of the patient characteristics between P2Y12 reaction unit hypo-response and normal or hyper-response.
| Variables | Hypo-response | Normal or hyper-response | p value |
|---|---|---|---|
| n = 6 | n = 37 | ||
| Age, years | 72 (71–76) | 72 (68–76) | 0.69 |
| Female sex | 2 (33.3%) | 4 (10.8%) | 0.19 |
| Hypertension | 4 (66.7%) | 32 (86.5%) | 0.25 |
| Diabetes mellitus | 3 (50.0%) | 14 (37.8%) | 0.67 |
| Hyperlipidemia | 4 (66.7%) | 19 (51.4%) | 0.67 |
| Coronary artery disease | 0 (0%) | 2 (5.4%) | 1 |
| Current smoking | 1 (16.7%) | 11 (29.7%) | 0.66 |
| Statin | 4 (66.7%) | 30 (81.1%) | 0.59 |
| Proton pump inhibitor | 5 (83.3%) | 31 (83.8%) | 1 |
| Cilostazol | 0 (0%) | 2 (5.4%) | 1 |
| Oral anti-coagulant | 0 (0%) | 3 (8.1%) | 1 |
| Duration of clopidogrel use before treatment, days | 22 (18.0–26.8) | 41 (20.0–88.0) | 0.25 |
| Hemoglobin, g/dL | 10.5 (10.1–11.0) | 14.1 (13.1–14.5) | 0.01† |
| Platelets, ×103/mL | 17.4 (15.0–25.5) | 21.5 (19.1–25.3) | 0.20 |
| Serum albumin, mg/dL | 3.4 (2.8–3.6) | 4.3 (4.1–4.4) | <0.001† |
| Preprocedural ARU | 422.5 (411.5–520.5) | 406.0 (388.0–494.0) | 0.10 |
| Symptomatic lesion | 5 (83.3%) | 16 (43.2%) | 0.09 |
| NASCET, %* | 74.6 (66.1–88.4) | 69.3 (59.6–78.9) | 0.21 |
Continuous variables are presented as median (interquartile range).
*The degree of carotid artery stenosis measured using the NASCET method.
†Statistically significant in the Mann–Whitney U test.
ARU: aspirin reaction unit; NASCET: North American Symptomatic Carotid Endarterectomy Trial